You are here

Home » Content

GASTRO RETENTIVE FLOATING DRUG DELIVERY SYSTEM: A REVIEW

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2013

Key Words:

Author NameUniversity of Author
Abstract (2. Language): 
Controlled release (CR) dosage forms have been extensively used to improve therapy with several important drugs. However, the development processes are faced with several physiological difficulties. Such as the inability to restrain and localize the system within the desired region of the gastrointestinal tract and the highly variable nature of the gastric emptying process. This variability may lead to unpredictable bioavailability and times to achieve peak plasma levels. On the other hand, incorporation of the drug in a controlled release gastroretentive dosage forms (CR-GRDF) which can remain in the gastric region for several hours would significantly prolong the gastric residence time of drugs and improve bioavailability, reduce drug waste, and enhance the solubility of drugs that are less soluble in high pH environment. Gastroretention would also facilitate local drug delivery to the stomach and proximal small intestine. Thus, gastro retention could help to provide greater availability of new products and consequently improved therapeutic activity and substantial benefits to patients. Controlled gastric retention of solid dosage form may be achieved by the mechanisms of floatation, mucoadhesion, sedimentation, expansion or by a modified shaped system. The purpose of this paper is to review the recent literature and current technology used in the development of gastroretentive dosage forms.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon ijprbs_278.pdf
  • 2
358-377
  • English

REFERENCES

References: 

1. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site specific delivery. Int J Pharm. 1996; 136: 117-139.
2. Singh BN and Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric
ISSN: 2277-8713
7 IJPRBS
retention. J. Control. Release. 2000; 63:
235-239.
3. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery system. Expert Opin Drug Deliv. 2006; 3 (2): 217¬233.
4. Ali J, Arora S, Khar RK. Floating drug delivery System: A Review. AAPS Pharm Sci
Tech. 2005; 06(03): E372-E390.
5. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res. 1997; 14: 815-819.
6. Davis SS, Stockwell AF, Taylor MJ. The effect of density on the gastric emptying of single and multiple unit dosage forms.
Pharm Res. 1986; 3: 208-213.
7. Lehr CM. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst. 1994; 11: 119-160.
8. Groning R, Heun G. Oral dosage forms with controlled gastrointestinal transit. Drug Dev Ind Pharm. 1984; 10: 527-539.
9. Groning R, Heun G. Dosage forms with controlled gastrointestinal passage studies
Available Online At www.ijprbs.com
Review Article
Manish Jaimini, IJPRBS,
2013; Volume 2(2): 358-377
ISSN: 2277-8713
IJPRBS
on the absorption of nitrofurantion. Int J
Pharm. 1989; 56: 111-116.
10. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release. 2003; 90:
143-162.
11. Timmermans J, Moes AJ. How well do floating dosage forms float. Int J Pharm.
1990; 62: 207- 16.
12. El-Kamel AH, Sokar MS, Al Gamal SS,
Naggar VF. Preparation and evaluation of ketoprofen floating oral delivery system. Int
J Pharm. 2001; 220: 13-21.
13. Oth M, Franz M, Timmermans J, Moes AJ. The bilayer floating capsule: A stomach-directed drug delivery system for misoprostol. Pharm Res. 1992; 9: 298-302.
14. Whitehead L, Fell JT, Collett JH, Sharma
HL, Smith AM. Floating dosage forms: An in vivo study demonstrating prolonged gastric retention. J Control Release. 1998; 55: 3-12.
15. Mojaverian P, Vlasses PH, Kellner PE, Rocci Jr ML. Effects of gender, posture, and age on gastric residence time of an indigestible solid: Pharmaceutical
considerations. Pharm. Res. 1988; 10: 639¬44.
16. Gansbeke BV, Timmermans J, Schoutens A, Moes AJ. Intragastric positioning of two concurrently ingested pharmaceutical matrix dosage forms. Nucl Med Biol. 1991; 18: 711-18.
17. Timmermans J, Moes AJ. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: New data for reconsidering the controversy. J Pharm Sci. 1994; 83: 18-24.
18. Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained release floating dosage form of amoxicillin
trihydrate. Int. J. Pham. 1992; 86: 79-88.
19. Seth PR, Tossounian J. The hydrodynamically balanced system, a novel drug delivery system for oral use. Drug Dev.
Ind Pharm. 1984; 10: 313-339.
20. Harrigan RM. Drug delivery device for preventing contact of undissolved drug with the stomach lining, US Patent 4, 055, 178,
October 25, 1977.
21. Whitehead L, Fell JT, Collett JH.
Development of a gastroretentive dosage
Available Online At www.ijprbs.com
Review Article
Manish Jaimini, IJPRBS,
2013; Volume 2(2): 358-377
form. Eur. J. Pharm. Sci. 1996; 4 (Suppl.): S 182.
22. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J. Pharm. Sci. 1992; 81: 135¬140.
23. Rubinstein A, Friend DR. Specific delivery to the gastrointestinal tract, In Domb AJ (Ed.) Polymeric site specific pharmacotherapy, Wiley, Chichester, 1994,
pp 282-283.
24. Stockwell AF, Davis SS, walker SE. In vitro evaluation of alginate gel system as sustained release drug delivery system. J
Control Release. 1986; 3: 167-175.
25. Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel gastroretentive dosage form: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm. Res. 2002; 19:
1516-1523.
26. Moes AJ. Gastroretentive Dosage forms. Crit. Rev. Ther. Drug Carrier Syst. 1993; 10: 143-195.
ISSN: 2277-8713 IJPRBS
27. Bechgaard H, Ladefoged K. Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J. Pharm.
Pharmacol. 1978; 30: 690- 692.
28. Klausner EA, Eyal S, Lavy E, Friedman M, Hoffman A. Novel Levodopa gastroretentive dosage form: in vivo evaluation in dogs. J.
Controlled release. 2003; 88: 117-126.
29. Hoffman A. Pharmacodynamic aspects of sustained release preparation. Adv. Drug
Deliv. Rev. 1998; 33: 185-199.
30. Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit. Rev. Ther. Drug carrier Syst.
1999; 16: 571-639.
31. Basak SC, Rahman J, Ramalingam M. Design and in vitro testing of a floatable gastroretentive tablet of metformin hydrochloride. Pharmazie. 2007; 62: 145¬148.
32. Jaimini M, Rana AC, Tanwar YS. Formulation and evaluation of famotidine floating tablet. Curr Drug Deliv. 2007; 4(1): 51-55.
Available Online At www.ijprbs.com
Review Article
Manish Jaimini, IJPRBS, 2013; Volume 2(2): 358-377
33. Badve SS, Sher P, Korde A, Pawar AP. Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery. Eur. J. Pharm. Biopharm. 2007; 65: 85-93.
34. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int. J.
Pharm. 2006; 316: 86-92.
35. Rahman Z, Ali M, Khar RK. Design and evaluation of bilayer floating tablets of captopril. Acta Pharm. 2006; 56: 49-57.
36. Xiaoqiang Xu, Minije S, Feng Z, Yiqiao Hu. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: In vitro and in vivo evaluation in healthy volunteers. Int J
Pharm. 2006; 310:139-145.
37. Sharma S, Pawar A, Low density multiparticulate system for pulsatile release of meloxicam. Int J Pharm. 2006; 313: 150¬158.
38. Srivastava AK, Ridhurkar DN, Wadhwa S. Floating microspheres of cimetidine: formulation, characterization and in vitro evaluation. Acta. Pharm. 2005; 55: 277-285.
ISSN: 2277-8713
IJPRBS
39. Chavanpatil M, Jain P, Chaudhari S, Shear R, Vavia P. Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation. Int J Pharm. 2005; 304: 178-184.
40. Jain SK, Awasthi AM, Jain NK, Agarwal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. J. Control. Release. 2005;
107: 300-309.
41. Patel VF, Patel NM, Yeole PG. Studies on
formulation and evaluation of ranitidine floating tablets. Indian J. Pharm. Sci. 2005; 67(6): 703- 709.
42. Muthusamy K, Govindarajan G, Ravi T K. Preparation and Evaluation of Lansoprazole Floating Micropellets. Indian J. Pharm. Sci.
2005; 67(1): 75-79.
43. Sato Y, Kawashima Y, Takeuchi H, Yamamoto Y, Fujibayashi Y. Pharmacoscintigraphic Evaluation of Riboflavin Containing Microballons for a Floating Controlled Drug Delivery System in Healthy Humans. J. Control. Rel. 2004; 98: 75- 85.
Available Online At www.ijprbs.com
Review Article
Manish Jaimini, IJPRBS,
2013; Volume 2(2): 358-377
44. Dave BS, Amin AF, Patel MM. Gastroretentive Drug Delivery System of Ranitidine hydrochloride: formulation and invitro evaluation. AAPS Pharm. Sci. Tech.
2004; 5(2): article 34.
45. Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. Invitro and in vivo Evaluation of riboflavincontaining microballons for a Floating controlled drug delivery system in healthy humans. Int. J. Pharm. 2004; 275: 97-107.
46. Umamaheshwari
RB
, Jain S, Bhadra D, Jain NK. Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori. J Pharm. Pharmacol.
2003; 55(12): 1607-1613.
47. El-Gibaly. Development and Invitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non floating chitosan microspheres. Int. J.
Pharm. 2002; 249: 7-21.
48. Streubel A, Siepmann I, Bodmeier R. Floating matrix tablet based on Low Density
ISSN: 2277-8713 IJPRBS
Foam Powder: effects of formulation and processing parameters on drug release. Eur. J. Pharm. Biopharm. 2002; 18: 37-45.
49. Joseph NJ, Lakshmi S, Jayakrishnan A. A
Floating Type Oral Dosage Form for Piroxicam Based on Hollow Polycarbonate Microspheres: in vitro and in vivo evaluation in rabbits. J. Control. Rel. 2002;
79: 71-79.
50. Choi BY, Park HJ, Hwang SJ, Park JB.
Preparation of Alginate Beads for Floating Drug Delivery System: Effect of Co2 gas Forming Agents. Int. J. Pharm. 2002; 239: 81-91.
51. El-Kamel AH, Sokar MS, AlGamal SS,
Naggar VF. Preparation and evaluation of ketoprofen floating oral drug delivery
system. Int. J. Pharm. 2001; 220:13-21.

Thank you for copying data from http://www.arastirmax.com